1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
19.35 USD   +2.65%
05/26CUREVAC N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Form 6-K
PU
05/26CUREVAC N : Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development - Form 6-K
PU
05/26CUREVAC N : Announces Financial Results for the First Quarter of 2022 and Provides Business Update - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Drifting Lower in Friday Trade

01/21/2022 | 01:08pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
APPLIED DNA SCIENCES, INC. 4.24% 1.23 Delayed Quote.-69.40%
CUREVAC N.V. 2.65% 19.35 Delayed Quote.-43.60%
MEDTRONIC PLC -0.36% 99.08 Delayed Quote.-4.22%
NASDAQ COMP. 3.33% 12131.13 Real-time Quote.-22.46%
All news about CUREVAC N.V.
05/26CUREVAC N : Interim Condensed Consolidated Statements of Operations and Other Comprehensiv..
PU
05/26CUREVAC N : Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Va..
PU
05/26CUREVAC N : Announces Financial Results for the First Quarter of 2022 and Provides Busines..
PU
05/25CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/25CureVac N.V. and myNEO N.V. Enters into a Research and Option Agreement
CI
05/25CureVac Working With myNEO to Develop New mRNA Immunotherapies
MT
05/25CureVac Narrows Q1 Pre-Tax Loss as Revenue Rises
MT
05/25CureVac Announces Financial Results for the First Quarter of 2022 and Provides Busines..
EQ
05/25CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vac..
EQ
05/10TRANSCRIPT : CureVac N.V. Presents at Bank of America 2022 Healthcare Conference, May-10-2..
CI
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2022 76,6 M 82,0 M 82,0 M
Net income 2022 -130 M -140 M -140 M
Net cash 2022 507 M 543 M 543 M
P/E ratio 2022 -26,0x
Yield 2022 -
Capitalization 3 378 M 3 619 M 3 619 M
EV / Sales 2022 37,5x
EV / Sales 2023 20,1x
Nbr of Employees 824
Free-Float 99,0%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 18,06 €
Average target price 25,30 €
Spread / Average Target 40,1%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean Stéphenne Chairman-Supervisory Board
Igor Splawski Chief Scientific Officer
Malte Greune Chief Operating & Production Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-43.60%3 619
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478